Early Treatment with Interferon provides better Patient Outcomes - Second in ASH 2016 Series, PV Reporter - pvreporter.com/dr-kiladjian...
Dr Kiladjian at ASH 2016 Reviews Outcomes of MPN... - MPN Voice
Dr Kiladjian at ASH 2016 Reviews Outcomes of MPN Patients after Interferon therapy discontinuation
Written by
PVReporter
To view profiles and participate in discussions please or .
Read more about...
4 Replies
•
Very interesting - I was part of the 15% who were taken off Pegasys not for toxicity or remission reasons; JJK advised me to stop Pegasys and go for a SCT.
Such a humble and approachable man.
Thanks for the reporting.
Crapaud
I hope your SCT has gone well. Glad you enjoyed the interview. I was excited to get the opportunity, it was a pleasure to discuss his latest research on interferon
Best,
David - PV Reporter
That's good news Crapaud, I hope you get the cGvHD smoothed out. Always nice to spend time with the family and have future projects to keep you busy!
Best,
David
Not what you're looking for?
You may also like...
ASH paper re younger MPN patients, dx age <= 40
younger MPN patients so thought I would highlight this one that is being presented at the ASH...
A Conversation with an MPN Specialist: ASH Updates - Dr. Andrew Kuykendall
presentations from the recent meeting of ASH from our friends at MPN Advocacy & Education...
10 facts MPN patients need to know about FDA approval of Ropegylated interferon alpha2b (Besremi).
Cancer Center, and MPN expert and investigator, discusses the top 10 facts that patients with...
Dr Verstovsek on Besremi and Outcomes
targetedonc.com/view/first-fda-approved-interferon-improves-outcomes-in-polycythemia-vera
Interferons as the First Choice of Cytoreduction in ET and PV
used in the treatment of cancers, including hematologic malignancies. Use of standard interferon...